KINETA INC (KA)
US49461C1027 - Common Stock
Which stocks are moving before the opening bell on Monday?
Get insights into the top gainers and losers of Monday's pre-market session.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to know about on Monday!
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to...
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We have all of the biggest pre-market stock movers that investors are going to want to keep an eye on for Monday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning!
KA Stock Earnings: Kineta Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kineta (NASDAQ:KA) just reported results for the first quarter of 2024.Kineta r...
KA Stock Earnings: Kineta Misses EPS for Q1 2024
KA stock results show that Kineta missed analyst estimates for earnings per share the first quarter of 2024.
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety...
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
KA Stock Earnings: Kineta Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kineta (NASDAQ:KA) just reported results for the fourth quarter of 2023.Kineta ...
KA Stock Earnings: Kineta Beats EPS for Q4 2023
KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!